Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease

Carol Addy, Chris Assaid, David Hreniuk, Mark Stroh, Yang Xu, W. Joseph Herring, Aaron Ellenbogen, H. A. Jinnah, Louis Kirby, Mark T. Leibowitz, R. Malcolm Stewart, Daniel Tarsy, James Tetrud, S. Aubrey Stoch, Keith Gottesdiener, John Wagner

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Fingerprint

Dive into the research topics of 'Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease'. Together they form a unique fingerprint.

Medicine & Life Sciences